EVNIN LUKE 4

What Happened

• Luke Evnin, a director (and manager of related MPM entities), sold a total of 141,106 Werewolf Therapeutics (HOWL) shares in three open‑market disposals from May 27–29, 2026 under a Rule 10b5‑1 plan. The sales were:
  • 05/27/2026: 80,852 shares at a weighted avg price $0.48 — proceeds ~$38,809 (sales executed across affiliated funds).
  • 05/28/2026: 27,698 shares at a weighted avg price $0.46 — proceeds ~$12,741.
  • 05/29/2026: 32,556 shares at a weighted avg price $0.45 — proceeds ~$14,650.
• Total proceeds across the three transactions were roughly $66,200. These were sales (disposals), which are often routine; the transactions were effected pursuant to a 10b5‑1 trading plan (see footnote).

Key Details

• Transaction dates & price ranges:
  • 05/27/2026: weighted avg $0.48 (individual trades ranged $0.455–$0.4858).
  • 05/28/2026: weighted avg $0.46 (individual trades ranged $0.46–$0.49705).
  • 05/29/2026: weighted avg $0.45 (individual trades ranged $0.44–$0.4557).
• Shares owned after the final sale (05/29/2026): 622,579 shares held across related entities (66,701 by AM LLC; 421,155 by MPM BioVentures 2014; 28,088 by BV2014(B); 14,493 by AM BV2014; 92,142 by MPM Oncology Innovations Fund).
• Sales were executed by affiliated funds as broken out per trade (e.g., AM LLC, BV 2014, BV 2014(B), AM BV2014, MPM OIF).
• Notable footnotes: Transactions effected pursuant to a Rule 10b5‑1 plan dated March 26, 2026; reporting person (Luke Evnin) is a member/manager of the listed entities and disclaims direct beneficial ownership except to the extent of pecuniary interest.
• Filing timeliness: Form 4 filed 2026‑05‑29 covering trades 05/27–05/29 — reported within the usual Form 4 reporting window.

Context

• These were straight sales by funds affiliated with Evnin (institutional/managed‑fund disposals), not option exercises or gifts. Sales under a 10b5‑1 plan are pre‑arranged and are commonly executed for liquidity or portfolio management rather than signaling new company views.